Back to Search Start Over

Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort

Authors :
Philippe Le Corvoisier
Salah Ferkal
Daniel Wendling
Philippe Goupille
Bijan Ghaleh
Emilie Sbidian
Laura Pina Vegas
Pascal Claudepierre
Alain Luciani
Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE)
Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Service de rhumatologie [CHU Henri Mondor]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor
EPI-PHARE (EPI-PHARE)
Caisse nationale d'assurance maladie des travailleurs salariés [CNAMTS]-Agence nationale de sécurité du médicament et des produits de santé [Saint-Denis] (ANSM)
Service de dermatologie [Mondor]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Epigénétique des infections virales et des maladies inflammatoires (UR 4266) (EPILAB)
Université de Franche-Comté (UFC)
Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)
Groupe innovation et ciblage cellulaire (GICC), EA 7501 [2018-...] (GICC EA 7501)
Université de Tours (UT)
Hôpital Henri Mondor
Institut Mondor de Recherche Biomédicale (IMRB)
Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB)
Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM)
CHU Bordeaux [Bordeaux]
Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
Plateforme de Ressources Biologiques [Henri Mondor AP-HP, Créteil] (PRB)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor
Clinical Epidemiology and Ageing : Geriatrie Soins Primaires et Santé Publique (CEpiA)
CHI Créteil
IMRB - PROTECT/'Pharmacologie et Technologies pour les Maladies Cardiovasculaires' [Créteil] (U955 Inserm - UPEC)
Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
VO, alexandra
Source :
Rheumatology, Rheumatology, Oxford University Press (OUP), 2022, 61 (4), pp.1487-1495. ⟨10.1093/rheumatology/keab565⟩
Publication Year :
2021
Publisher :
Oxford University Press (OUP), 2021.

Abstract

Objective The factors contributing to long-term remission in axial SpA (axSpA) are unclear. We aimed to characterize individuals with axSpA at the 5-year follow-up to identify baseline factors associated with remission. Methods We included all patients from the DESIR cohort (with recent-onset axSpA) with an available Ankylosing Spondylitis Disease Activity Score–CRP (ASDAS-CRP) at 5-year follow-up. Patients in remission (ASDAS-CRP Results Overall, 111/449 patients (25%) were in remission after 5 years. Among those never exposed to TNFi, 31% (77/247) were in remission compared with 17% (34/202) of those exposed to TNFi. Patients in remission after 5 years were more likely to be male, HLA-B27+, have a lower BMI, and a higher education level. Baseline factors associated with 5-year remission in patients never exposed to TNFi included lower BASDAI [adjusted odds ratio (ORa) 0.9, 95% CI: 0.8, 0.9) and history of peripheral arthritis (ORa 2.1, 95% CI: 1.2, 5.3). In those exposed to TNFi, remission was associated with higher education level (ORa 2.9, 95% CI: 1.6, 5.1), lower enthesitis index (ORa 0.8, 95% CI: 0.7, 0.9), lower BASDAI (ORa 0.9, 95% CI: 0.9, 0.9) and lower BMI (ORa 0.8, 95% CI: 0.7, 0.9). Conclusion This study highlights the difficulty in achieving 5-year remission in those with recent-onset axSpA, especially for the more active cases, despite the use of TNFi. Socio-economic factors and BMI are implicated in the outcome at 5 years.

Details

ISSN :
14620332, 14620324, and 14602172
Volume :
61
Database :
OpenAIRE
Journal :
Rheumatology
Accession number :
edsair.doi.dedup.....1a8ed4818eeb5c4a91ea4e838a57cfc6